Regeneron Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US75886F1075

SecurityREGN / Regeneron Pharmaceuticals, Inc.
InstitutionRYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity
Latest Disclosed Ownership607 shares
Latest Disclosed Value $ 318,675
RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity reports 9.57% increase in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On August 27, 2025 - RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity filed a NPORT-P form disclosing ownership of 607 shares of Regeneron Pharmaceuticals, Inc. (US:REGN) valued at $318,675 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 29, 2025 disclosing 554 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of 9.57% during the quarter. The current value of the position is $381,639 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-27 2025-06-30 NP Regeneron Pharmaceuticals EC US75886F1075 607 53 9.57 319 -9.40 3.5416
2025-05-29 2025-03-31 NP Regeneron Pharmaceuticals EC US75886F1075 554 7 1.28 351 -9.77 3.7326
2025-03-03 2024-12-31 NP Regeneron Pharmaceuticals EC US75886F1075 547 154 39.19 390 -5.81 3.9062
2024-11-29 2024-09-30 NP Regeneron Pharmaceuticals EC US75886F1075 393 -49 -11.09 413 -10.99 3.7420
2024-08-29 2024-06-30 NP Regeneron Pharmaceuticals EC US75886F1075 442 -183 -29.28 465 -22.80 4.2352
2024-05-30 2024-03-31 NP Regeneron Pharmaceuticals EC US75886F1075 625 35 5.93 602 16.02 5.1016
2024-02-29 2023-12-31 NP Regeneron Pharmaceuticals EC US75886F1075 590 -40 -6.35 518 0.00 4.2471
2023-11-29 2023-09-30 NP Regeneron Pharmaceuticals EC US75886F1075 630 -154 -19.64 518 -7.99 4.4890
2023-08-28 2023-06-30 NP Regeneron Pharmaceuticals EC US75886F1075 784 -2 -0.25 563 -12.71 4.4456
2023-05-30 2023-03-31 NP Regeneron Pharmaceuticals EC US75886F1075 786 -202 -20.45 646 -9.41 4.8917
2023-02-28 2022-12-31 NP Regeneron Pharmaceuticals EC US75886F1075 988 51 5.44 713 10.39 4.3109
2022-11-29 2022-09-30 NP Regeneron Pharmaceuticals EC US75886F1075 937 -86 -8.41 645 6.79 4.5045
2022-08-29 2022-06-30 NP Regeneron Pharmaceuticals EC US75886F1075 1,023 -28 -2.66 605 -17.71 4.1487
2022-05-26 2022-03-31 NP Regeneron Pharmaceuticals EC US75886F1075 1,051 -221 -17.37 734 -8.59 4.3375
2022-02-28 2021-12-31 NP Regeneron Pharmaceuticals EC US75886F1075 1,272 97 8.26 803 12.94 3.5496
2021-11-29 2021-09-30 NP Regeneron Pharmaceuticals EC US75886F1075 1,175 -163 -12.18 711 -4.82 2.9892
2021-08-27 2021-06-30 NP Regeneron Pharmaceuticals EC US75886F1075 1,338 -136 -9.23 747 7.17 3.1300
2021-05-27 2021-03-31 NP Regeneron Pharmaceuticals EC US75886F1075 1,474 -212 -12.57 697 -14.37 3.1382
2021-03-01 2020-12-31 NP Regeneron Pharmaceuticals EC US75886F1075 1,686 -188 -10.03 815 -22.40 3.3172
2020-11-25 2020-09-30 NP Regeneron Pharmaceuticals EC US75886F1075 1,874 68 3.77 1,049 -6.84 4.3784
2020-08-27 2020-06-30 NP Regeneron Pharmaceuticals EC US75886F1075 1,806 -424 -19.01 1,126 3.49 4.5390
2020-06-01 2020-03-31 NP Regeneron Pharmaceuticals EC US75886F1075 2,230 -141 -5.95 1,089 22.25 6.6649
2020-03-02 2019-12-31 NP Regeneron Pharmaceuticals EC US75886F1075 2,371 -200 -7.78 890 24.82 4.1208
2019-11-27 2019-09-30 NP Regeneron Pharmaceuticals EC US75886F1075 2,571 2,571 713 3.7836
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.